|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0000744,
umls-concept:C0023473,
umls-concept:C0026882,
umls-concept:C0030705,
umls-concept:C0080279,
umls-concept:C0332325,
umls-concept:C0935989,
umls-concept:C1412097,
umls-concept:C1510438,
umls-concept:C1511790,
umls-concept:C1826328,
umls-concept:C2266681
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-7-1
|
|
pubmed:abstractText |
Despite the efficacy of the BCR-ABL tyrosine kinase inhibitor Imatinib mesylate for the treatment of chronic myeloid leukemia (CML), resistance has been observed in a proportion of cases, especially those with advanced stages of the disease. Point mutations within the ABL kinase domain are emerging as the most frequent mechanism for reactivation of kinase activity within the leukemic clone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0009-9147
|
|
pubmed:author |
pubmed-author:AmabileMarilinaM,
pubmed-author:BaccaraniMicheleM,
pubmed-author:BianchiniMicheleM,
pubmed-author:Italian Cooerative Study Group on Chronic Myeloid Leukemia,
pubmed-author:MartinelliGiovanniG,
pubmed-author:PaneFabrizioF,
pubmed-author:PoerioAngelaA,
pubmed-author:RostiGianantonioG,
pubmed-author:SaglioGiuseppeG,
pubmed-author:SoveriniSimonaS,
pubmed-author:TrueD LDL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
50
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1205-13
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15107311-Antineoplastic Agents,
pubmed-meshheading:15107311-Chromatography, High Pressure Liquid,
pubmed-meshheading:15107311-DNA Mutational Analysis,
pubmed-meshheading:15107311-Drug Resistance, Neoplasm,
pubmed-meshheading:15107311-Fusion Proteins, bcr-abl,
pubmed-meshheading:15107311-Genes, abl,
pubmed-meshheading:15107311-Humans,
pubmed-meshheading:15107311-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:15107311-Piperazines,
pubmed-meshheading:15107311-Point Mutation,
pubmed-meshheading:15107311-Protein-Tyrosine Kinases,
pubmed-meshheading:15107311-Pyrimidines,
pubmed-meshheading:15107311-Retrospective Studies,
pubmed-meshheading:15107311-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:15107311-Sensitivity and Specificity
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.
|
|
pubmed:affiliation |
Institute of Hematology and Medical Oncology Seràgnoli, University of Bologna, Bologna, Italy.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
